RxDoctor Payments Data

Jeffrey Deweerd, DO

Family Medicine · Mason, MINPI 1669428827

Payments from drug & device makers

$978in general payments, 2019–2025

Across 63 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • Takeda Pharmaceuticals U.S.A., Inc.$117
  • AbbVie$109
  • Pfizer$96
  • AstraZeneca$92
  • Lilly USA, LLC$80
  • plus $235 from 8 others

What the payments were for

  • Food & beverage$94897%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$978 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$48,159
Medicare patients
86
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tetrabenazine11$57,923
EliquisApixaban49$56,237
TrulicityDulaglutide25$49,931
JanuviaSitagliptin Phosphate43$45,395
FarxigaDapagliflozin Propanediol32$36,596
OzempicSemaglutide29$31,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,714
JardianceEmpagliflozin23$18,737
VraylarCariprazine Hcl13$18,269
XareltoRivaroxaban13$16,049
Novolog FlexpenInsulin Aspart28$7,972
Breo ElliptaFluticasone/Vilanterol13$5,146
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$5,025
Testosterone12$4,494
Olmesartan Medoxomil133$4,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$96$56,23749 claims
Lilly USA, LLCTrulicity$80$49,93125 claims
MerckJanuvia$47$45,39543 claims
AstraZenecaFarxiga$92$36,59632 claims
Novo NordiskOzempic$248$31,89729 claims
GSKTrelegy Ellipta, Breo Ellipta$48$24,86133 claims
AbbVieVraylar$109$18,26913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Mason

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →